Abstract
Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.
| Original language | English |
|---|---|
| Pages (from-to) | 117-123 |
| Number of pages | 7 |
| Journal | Future Cardiology |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Adenosine A1 receptor antagonist
- Cardiorenal syndrome
- Heart failure
- KW-3902
- Natriuresis
- Renal function
- Rolofylline
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Molecular Medicine
Cite this
Rolofylline (KW-3902) : A new adenosine A1-receptor antagonist for acute congestive heart failure. / Chaparro, Sandra; Dittrich, Howard C.; Tang, W. H Wilson.
In: Future Cardiology, Vol. 4, No. 2, 01.03.2008, p. 117-123.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rolofylline (KW-3902)
T2 - A new adenosine A1-receptor antagonist for acute congestive heart failure
AU - Chaparro, Sandra
AU - Dittrich, Howard C.
AU - Tang, W. H Wilson
PY - 2008/3/1
Y1 - 2008/3/1
N2 - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.
AB - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.
KW - Adenosine A1 receptor antagonist
KW - Cardiorenal syndrome
KW - Heart failure
KW - KW-3902
KW - Natriuresis
KW - Renal function
KW - Rolofylline
UR - http://www.scopus.com/inward/record.url?scp=40649115008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40649115008&partnerID=8YFLogxK
U2 - 10.2217/14796678.4.2.117
DO - 10.2217/14796678.4.2.117
M3 - Article
C2 - 19804290
AN - SCOPUS:40649115008
VL - 4
SP - 117
EP - 123
JO - Future Cardiology
JF - Future Cardiology
SN - 1479-6678
IS - 2
ER -